Literature DB >> 18455642

Risk attitudes to treatment among patients with severe intermittent claudication.

Anna Letterstål1, Christina Forsberg, Pär Olofsson, Eric Wahlberg.   

Abstract

OBJECTIVES: To determine claudication patients' risk attitude to invasive treatment and whether this treatment is cost effective.
METHODS: Quality of life and health state utility status of 50 consecutive patients with severe intermittent claudication was assessed and compared with ankle-brachial pressure index values (ABPI) and results from treadmill tests before and after endovascular or open revascularization. Health utility scores were then calculated and used in a cost-utility analysis.
RESULTS: Before surgery, patients were assigned a utility score of 0.51 (EQ-5D index) for their disease, and the standard gamble (SG) and time trade-off (TTO) median scores were 0.88 and 0.70, respectively. Before treatment, a weak correlation (r = 0.43, P < .001) between having a high risk perception of treatment and patients' walking distance were observed, where patients able to walk short distances accepted a higher risk. After treatment, ABI (P = .003) and walking distance (P = .002) improved significantly as well the physical components of the quality of life instruments (P < .001). The surgical treatment generated an improvement in quality of life expressed in QALYs equivalent to 0.17. With an estimated survival of 5 years, it adds up to a value of 0.85, corresponding to a sum of 51,000 US dollars gained.
CONCLUSIONS: Patients with severe intermittent claudication are risk-seeking when it comes to surgical treatment and their risk attitude is correlated to their walking ability and quality of life. The incremental QALYs gained by treatment are achieved at a reasonable cost and revascularization appears to be cost effective.

Entities:  

Mesh:

Year:  2008        PMID: 18455642     DOI: 10.1016/j.jvs.2007.12.055

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  1 in total

1.  Therapy for peripheral artery disease: gaps in treating patients with claudication.

Authors:  Ryan J Mays; Judith G Regensteiner
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.